Filing Flows › Bionano Genomics (BNGO) › Q4 2025
Bionano Genomics (BNGO) Q4 2025 earnings results (fourth quarter 2025)
10-K filed Mar 23, 2026
Bionano Genomics (BNGO) reported revenue of $8.0M for the fourth quarter 2025 (Q4 2025), -3% from a year earlier and +8% from the quarter before. Operating margin was -107.4%, net loss $7.9M (99.8% of revenue).
Bionano Genomics, Q4 2025: revenue $8.0M (-3% year over year), operating margin -107.4%, net loss $7.9M, operating cash flow −$4.2M. The chart follows the revenue to costs, profit and cash.
| Q4 2025 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $8.0M | +8% | -3% |
| Operating profit | −$8.5M | — | — |
| Net earnings | −$7.9M | — | — |
| Operating cash flow | −$4.2M | — | — |
What changed
Revenue was $8.0M in Q4 2025, down 3% year over year and up 8% from the previous quarter. Product was the largest line at 94% of revenue.
Operating costs exceeded revenue by $8.5M, an operating margin of -107.4%. Total costs fell 18% while revenue fell 3%. The quarter ended with a net loss of $7.9M, narrower than the previous quarter's $8.5M loss.
Operating cash flow was −$4.2M. Non-cash charges added back $2.3M of depreciation and amortization and $926K of share-based compensation. Working capital and other items added $495K.
Questions
What was Bionano Genomics' revenue in the fourth quarter 2025?
Bionano Genomics (BNGO) reported revenue of $8.0M for the fourth quarter 2025 (Q4 2025), -3% from a year earlier and +8% from the quarter before.
Was Bionano Genomics profitable in the fourth quarter 2025?
Operating loss was $8.5M (-107.4% of revenue) and net loss $7.9M.
Source: Bionano Genomics 10-K on SEC EDGAR.